Patients

Join our highway towards a cure

Currently, less than 5% of patients participate in clinical trials. TRICALS aims to open clinical trials to all people with ALS – giving them and their loved ones the chance to make a meaningful contribution to ridding the world of ALS, forever.

The direct involvement of people with ALS is essential and urgent. Each person with ALS holds an important piece of the puzzle, and putting the puzzle together will help us to find new and more effective treatments. We believe that with our new approach, where we all work together, we can make the difference. We can turn ALS into a condition that is treatable. When we all work together, we can build a highway towards a cure.

How does TRICALS work?

TRICALS aims to speed up the development of new medicines for ALS. To effectively do that, the direct involvement of people with ALS is essential and urgent. Each person with ALS holds an important piece of the puzzle, and putting the puzzle together will help us to find new and more effective treatments.

You can help by registering with TRICALS. After your permission, we will inform you on trials that are recruiting patients and you will be invited to an ALS centre that you choose, for further counselling and screening. Even if there are no suitable trials, your participation will help us to further unravel this complex disease by submitting your data, and participating in other types of scientific research.

Step 1

Register as a patient

If you are living with ALS (also known as MND) you can register for TRICALS. During your registration you will be asked for your personal details and to submit some basic information about how ALS affects you.

Step 2

Pre-screening questionnaire

When you have successfully registered, we will send you an online pre-screening questionnaire. Trained staff from your country’s TRICALS centre will then evaluate your responses

Step 3

Screening & participating

When you fulfill the minimum requirements of an active or new trial, you will be invited for screening in one of the participating trial centres in your country. If you fulfil all the requirements, you can participate in the trial.

Our mission is simple: find an effective treatment for patients with ALS

Josefina - patient

Strength in unity

“I would say that there is strength in unity. Although there are only few of us, if we all contribute a grain of sand, in the end we can build a beach”

Mia - patient

Making a difference

“I find it important as a patient to have an influence and to convince other patients that they will join and make a difference”

Current trials

Recruiting

Phase i

PRO-101 trial

Gesponsorde Trial

Recruiting

Phase i

VRG50635 study

Industry trial

Verge Genomics is conducting a phase 1b trial to evaluate the safety, tolerability, and potential efficacy of VRG50635 for people with Amyotrophic Lateral Sclerosis (ALS).

Active

Phase ii

DAZALS trial

Industry trial

In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS (also known as MND) to understand its safety (side effects) and to determine if dazucorilant can slow down the worsening of the disease. The effects of dazucorilant will be compared to the effects of a placebo. This study is sponsored by Corcept Therapeutics.

Active

Phase ii

CARDINALS

Industry trial

The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms. Researchers will also test the safety and tolerability of the study drug and how the body responds to it. The study drug is a liquid that is swallowed 2 times a day.

Recruiting

Phase ii

AP101-02

Industry trial

In this study we investigate the safety, tolerability, pharmacodynamics markers and pharmacokinetics (how a drug is absorbed and excreted) of AP-101 in patients with familial and sporadic amyotrophic lateral sclerosis (ALS). Currently, we are only looking for patients with familial ALS (caused by a SOD1 gene mutation) to participate in the study. This study is sponsored by AL-S Pharma.

Recruiting

Phase iii

ATLAS trial

Industry trial

Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.

Recruiting

Phase iii

FUSION trial

Industry trial

In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.

Completed

Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.

Completed

Phase iii

ADORE trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Completed

Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

TRICALS aims to speed up the development of new medicines for ALS. You can help by registering with TRICALS. The participation of patients in clinical trials is necessary to find better treatments.